MPS Enzyme Screening Reagents for Newborn Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for newborn screening of mucopolysaccharidoses (MPS) lack efficient and reliable techniques for early detection of MPS I, II, IIIA, IIIB, IVA, VI, and VII, which are essential for timely treatment and preventing irreversible organ damage.
Innovation Solution
Development of reagents and methods involving enzyme substrates with specific carbohydrate and aglycone moieties for lysosomal enzymes, allowing for the determination of enzyme activity in dried blood spots through incubation and mass spectrometric analysis, including the use of internal standards and glycohydrolases to enhance sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional newborn screening methods are used for MPS, then screening can be performed, but the detection sensitivity and reliability are insufficient for early diagnosis
Solution Approach 1:
The patent employs mass spectrometric analysis to detect and quantify enzyme products, representing a significant parameter change from conventional screening methods. This enables highly sensitive detection of enzyme activities associated with MPS I, II, IIIA, IIIB, IVA, VI, and VII by measuring product formation rates with precise mass spectrometry, thereby improving both detection sensitivity and screening reliability
Solution Approach 2:
The patent introduces specific enzyme substrates as intermediaries that react with lysosomal enzymes to produce detectable products. These substrates serve as mediators between the enzyme activities and the mass spectrometric detection system, enabling reliable quantification of enzyme functions that would otherwise be difficult to measure directly
2Loss of time
If early detection methods are developed, then treatment can be initiated before irreversible damage, but the screening process becomes more complex
Solution Approach 1:
The patent segments the screening process into distinct enzymatic reactions, each targeting specific lysosomal enzymes (alpha-L-iduronidase, iduronate 2-sulfatase, heparan N-sulfatase, N-acetyl-alpha-D-glucosaminidase, N-acetylgalactosamine 6-sulfate-sulfatase, N-acetylgalactosamine 4-sulfate-sulfatase, and beta-glucuronidase). This segmentation allows parallel analysis of multiple enzymes through standardized mass spectrometric detection, reducing overall diagnostic time while managing complexity through systematic organization
Solution Approach 2:
The patent employs a universal mass spectrometric detection platform that can analyze multiple different enzyme activities using a common analytical approach. This multi-functional system handles screening for all seven MPS types (I, II, IIIA, IIIB, IVA, VI, and VII) through a unified methodology, reducing the need for separate specialized tests and accelerating comprehensive diagnosis
3Ease of operation
If dried blood spots are used as sample source, then screening becomes less invasive, but the enzyme activity measurement becomes more difficult
Solution Approach 1:
The patent incorporates preliminary enzymatic incubation steps where enzyme substrates are pre-added to the dried blood spot samples before analysis. This preliminary action allows enzyme activities to be captured and product formation to occur while the enzymes are still present in the dried blood spot matrix, overcoming the measurement difficulties associated with this sample type and enabling reliable detection despite the challenging matrix
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables fast, inexpensive, and reliable screening for MPS enzymes, facilitating early diagnosis and potential treatment benefits by accurately quantifying enzyme products and differentiating between enzyme activities, thereby supporting timely intervention.
Implementation Method 1
contacting the one or more lysosomal enzymes in solution with an enzyme substrate for each lysosomal enzyme to be analyzed and incubating the substrates with the enzymes for a time sufficient to provide a solution comprising an enzyme product for each lysosomal enzyme present in the sample
Implementation Method 2
determining the quantities of one or more of the enzyme products
Data Source
AI summary
Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.